Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4208169 | 0.79 | KMT2A (0.54) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1889092 | 0.79 | BAZ2B (0.50) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4740932 | 0.79 | KMT2A (0.46) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL28079721 | 0.75 | KMT2A (0.50) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11480120 | 0.75 | KMT2A (0.46) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15381202 | 0.75 | RAB9A (0.47) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8862850 | 0.75 | CTH (0.50) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5381046 | 0.74 | KDM4E (0.69) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4433427 | 0.73 | KMT2A (0.45) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1934753 | 0.72 | RAB9A (0.57) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | KMT2A 3194/4885KDM4E 4294/4885RAB9A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.